Exane BNP Paribas upgraded Genmab (GMAB) to Neutral from Underperform with a DKK 1,500 price target. The firm sees a “reasonable” valuation at current share levels and views the upcoming CagriSema readout from Novo Nordisk (NVO) as a “positively skewed catalyst.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GMAB:
Questions or Comments about the article? Write to editor@tipranks.com